Evolent Health, Inc EVH
3.61
0.09
2.56%
as of 25 Sep
- Market cap
- $398.0M
- P/E
- 0.0×
Follow EVH
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.47 | 0.24 | 0.14 | 0.29 | |
P/FCF ratio |
0.00 | 96.07 | 182.90 | 25.06 | |
P/Operating CF |
61.03 | 9.36 | (259.29) | (65.50) | |
P/B ratio |
1.15 | 1.10 | 0.64 | 1.59 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.92 | 0.67 | 0.56 | 0.69 | |
EV/EBITDA |
20.39 | 10.56 | 9.81 | 14.39 | |
EV/Operating CF |
(51.94) | 32.16 | 31.92 | 26.47 | |
EV/FCF |
(27.37) | 262.75 | 761.74 | 59.07 | |
Quick Ratio |
1.23 | 1.27 | 1.26 | 1.19 | |
Current Ratio |
1.33 | 1.31 | 1.32 | 1.24 | |
Net Debt/EBITDA |
30.44 | 20.35 | 54.43 | 51.48 | |
Debt/Assets |
42.99% | 51.10% | 51.81% | 49.01% | |
Debt/Equity |
1.25 | 2.34 | 2.46 | 2.52 | |
Asset Turnover |
0.83 | 0.84 | 0.83 | 0.95 | |
Operating CF/Net income |
(0.59) | (0.11) | 0.04 | 0.33 | |
Capex/Depreciation |
(0.31) | (0.02) | (0.25) | (0.27) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
16.18% | 15.50% | 14.67% | 10.55% | |
Intangible Assets out of Total Assets |
0.69 | 0.67 | 0.67 | 0.63 | |
Share Based Compensation of Revenue |
3.06% | 0.51% | 2.15% | 2.33% | |
Graham Net Nets |
(1.08) | (2.14) | (3.84) | (1.60) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(18.68%) | (128.75%) | (208.77%) | (84.32%) | |
Free Cash Flow Yield |
(7.12%) | 1.04% | 0.55% | 3.99% | |
Revenue per Share |
4.20 | 4.10 | 4.43 | 5.80 | |
Operating CF per Share |
0.14 | 0.43 | (0.01) | (0.08) | |
Capex per Share |
(0.08) | (0.07) | (0.06) | (0.06) | |
Free Cash Flow per Share |
0.06 | 0.36 | (0.07) | (0.14) | |
Cash per Share |
1.23 | 1.56 | 1.48 | 1.23 | |
Shareholders Equity per Share |
7.38 | 3.64 | 3.54 | 3.41 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.38 | 3.64 | 3.54 | 3.41 | |
Free Cash Flow |
6.85 | 41.04 | (7.39) | (16.16) | |
Working Capital |
140.17 | 121.11 | 120.78 | 117.68 | |
Capital Expenditures |
(8.96) | (7.76) | (6.41) | (6.85) | |
Net Current Asset Value |
(1,041.13) | (977.67) | (980.44) | (978.16) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.02 | 0.01 | 0.01 | |
Net Profit Margin |
(5.62%) | (91.55%) | (5.37%) | (4.35%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
397.23 | 362.27 | 372.33 | 403.94 | |
Average Payables |
61.13 | 77.90 | 60.41 | 54.14 | |
Average Assets |
2,477.61 | 2,221.82 | 2,266.15 | 2,216.71 | |
Average Common Equity |
940.46 | 708.23 | 665.96 | 639.61 |
Columns are period end dates